ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Use of Tacrolimus Extended-Release in Elderly Kidney Transplant Recipients

S. January1, J. Hagopian1, N. Nesselhauf1, K. Progar1, R. Delos Santos2

1Barnes-Jewish Hospital, Saint Louis, MO, 2Washington University, Saint Louis, MO

Meeting: 2020 American Transplant Congress

Abstract number: B-112

Keywords: Elderly patients, Immunosuppression, Kidney transplantation

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session B: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
  • 2-Year Results of a Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients

*Purpose: Tacrolimus extended-release (LCPT) has been associated with efficacy and decreased rates of tremor when compared with tacrolimus immediate-release (Tac-IR) in kidney transplant recipients. Patients ≥ 65 years old are not well represented in previously published studies; the purpose of this study is to supplement existing literature of efficacy and safety of LCPT in elderly patients.

*Methods: We performed a retrospective, single center cohort analysis of adult kidney transplant recipients from 1/2015 to 6/2017 who received either Tac-IR or LCPT and remained on the same formulation for at least one year post-transplant. The primary outcome was a composite of graft loss, death, or biopsy-proven acute rejection (BPAR) at two years post-transplant; secondary outcomes included GFR and tremor differences. To determine if elderly patients have the same weight-based dose requirement to attain target trough level, LCPT dosing was compared between patients ≥ 65 and <65 years of age. Between group differences were evaluated using Chi-square and independent samples t-test where appropriate.

*Results: 89 kidney transplant patients aged 65 or older received either LCPT (n=52) or Tac-IR (n=37). Baseline characteristics were well matched between the two groups; the average age was 69.1 years in LCPT and 67.8 years in Tac-IR group (P=0.22). There were no differences in sex, race, type of induction, duration of dialysis, or type of donor between groups. The primary composite outcome of graft loss, death, or BPAR occurred in 15.4% of patients in the LCPT arm and 8.1% in the Tac-IR arm (P=0.30). Median GFR at two years post-transplant was 57.0 mL/min (IQR 49.2, 71.7) in LCPT patients compared with 57.0 mL/min (IQR 49.2, 71.7) in Tac-IR patients (P=0.68). There were no significant differences in tremor between groups. Comparison of weight based dosing in patients ≥65 and <65 years old revealed at all time points elderly patients required less tacrolimus as shown in Table 1.

Age ≥65 (n=52) Age <65 (n=176) P-value
30 day mg/kg tacrolimus dose (mean ± SD) 0.06 ± 0.03 0.08 ± 0.04 <0.01
90 day mg/kg tacrolimus dose (mean ± SD) 0.05 ± 0.03 0.06 ± 0.04 0.01
180 day mg/kg tacrolimus dose (mean ± SD) 0.03 ± 0.02 0.06 ± 0.04 <0.01
270 day mg/kg tacrolimus dose (mean ± SD) 0.03 ± 0.02 0.05 ± 0.04 <0.01
365 day mg/kg tacrolimus dose (mean ± SD) 0.03 ± 0.02 0.05 ± 0.04 <0.01

*Conclusions: Use of LCPT in elderly patients resulted in similar graft function and tremor in our population. Patients 65 years of age and older may require lower mg/kg doses of LCPT to attain therapeutic trough levels.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

January S, Hagopian J, Nesselhauf N, Progar K, Santos RDelos. Use of Tacrolimus Extended-Release in Elderly Kidney Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/use-of-tacrolimus-extended-release-in-elderly-kidney-transplant-recipients/. Accessed March 8, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Search
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.